Oncogenic mutations or other genetic alterations (e.g., gene amplification) have been found in RTKs, Ras, Raf and MEKs, but no activating mutations or genetic alterations in Erk molecules themselves have been reported as oncogenic in tumor viruses or in patients. This evidence concerns the gene RAF1 and neoplasm.